Physician profile
Mark A Gottlieb
NPI 1518073279
$5,896.82
in general payments reported to CMS, 2019-2025
17 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $296 · 2021: $753 · 2022: $1,552 · 2023: $499 · 2024: $794 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436 · Entertainment: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.12 |
| Entertainment | $107.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,196.46 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $685.56 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $668.05 | 2019-2025 | Dailies Total1, Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $601.77 | 2021-2025 | Acuvue |
| Coopervision INC. | $504.99 | 2019-2025 | Clariti Contact Lens |
| Dompe US, INC. | $327.04 | 2022-2024 | Oxervate |
| Abbvie INC. | $326.39 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $316.91 | 2022-2024 | |
| Glaukos Corporation | $313.90 | 2023-2025 | Ce-Marked Kxla System |
| Harrow Eye, LLC | $276.85 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $179.19 | 2022-2025 | |
| Sight Sciences, INC. | $147.20 | 2025 | Tearcare System |
| Optos, INC. | $107.58 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $99.61 | 2025 | |
| Oyster Point Pharma, INC. | $64.92 | 2022-2025 | Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $52.41 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $27.99 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.